Taysha Gene Therapies is Drug Discovery in United States that focus on Gene Therapies Inc business. Founded in 2019. They cover business area such as Taysha Gene Therapies Inc, monogenic CNS disease, aav-base gene therapy, monogenic disease, both rare and large patient population, transformative gene therapy treatment, exclusive option, four additional development program, its product candidate.
2019
( 7 years old in 2026 )
Gene Therapies Inc
-
BioCenter at UT Southwestern
2280 Inwood Road
Dallas, TX 75235
United States
Private
Taysha Gene Therapies Incmonogenic CNS diseaseaav-base gene therapymonogenic diseaseboth rare and large patient populationtransformative gene therapy treatmentexclusive optionfour additional development programits product candidate
* We use standard office opening hours in near Taysha Gene Therapies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Taysha Gene Therapies is Drug Discovery business from United States that founded in 2019 (7 years old in 2026), Taysha Gene Therapies business is focusing on Gene Therapies Inc.
Taysha Gene Therapies headquarter office and corporate office address is located in BioCenter at UT Southwestern 2280 Inwood Road Dallas, TX 75235 United States.
Taysha Gene Therapies was founded in United States.
In 2026, Taysha Gene Therapies is currently focus on Gene Therapies Inc sector.
Above is snippet of Google Trends for "Gene Therapies Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Taysha Gene Therapies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
